BR0314539A - Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade - Google Patents

Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade

Info

Publication number
BR0314539A
BR0314539A BR0314539-5A BR0314539A BR0314539A BR 0314539 A BR0314539 A BR 0314539A BR 0314539 A BR0314539 A BR 0314539A BR 0314539 A BR0314539 A BR 0314539A
Authority
BR
Brazil
Prior art keywords
association
ppar
antioxidant
binder
obesity treatment
Prior art date
Application number
BR0314539-5A
Other languages
English (en)
Inventor
Louis Casteilla
Luc Penicaud
Catherine Dacquet
Pierre Renard
Original Assignee
Servier Lab
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Centre Nat Rech Scient filed Critical Servier Lab
Publication of BR0314539A publication Critical patent/BR0314539A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ASSOCIAçãO ENTRE UM LIGANTE DOS PPAR E UM AGENTE ANTIOXIDANTE E UTILIZAçãO NO TRATAMENTO DA OBESIDADE". A presente invenção refere-se a uma associação que contém um ou vários ligantes dos receptores ativados pelos proliferadores de peroxisomas e um agente antioxidante. Medicamentos.
BR0314539-5A 2002-10-11 2003-10-10 Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade BR0314539A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212646A FR2845602B1 (fr) 2002-10-11 2002-10-11 Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
PCT/FR2003/002986 WO2004032967A1 (fr) 2002-10-11 2003-10-10 Association entre un ligand des ppar et un agent antioxydant et utilisation dans le traitement de l'obesite

Publications (1)

Publication Number Publication Date
BR0314539A true BR0314539A (pt) 2005-07-26

Family

ID=32039639

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314539-5A BR0314539A (pt) 2002-10-11 2003-10-10 Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade

Country Status (20)

Country Link
US (1) US20060002911A1 (pt)
EP (2) EP1549348A1 (pt)
JP (1) JP2006505548A (pt)
KR (1) KR20050072759A (pt)
CN (1) CN100571776C (pt)
AR (1) AR041579A1 (pt)
AU (1) AU2003299772C1 (pt)
BR (1) BR0314539A (pt)
CA (1) CA2501964A1 (pt)
EA (1) EA010353B1 (pt)
FR (1) FR2845602B1 (pt)
GE (1) GEP20084462B (pt)
MA (1) MA27402A1 (pt)
MX (1) MXPA05003893A (pt)
MY (1) MY140562A (pt)
NO (1) NO20052231L (pt)
NZ (2) NZ566708A (pt)
PL (1) PL376045A1 (pt)
UA (1) UA81132C2 (pt)
WO (1) WO2004032967A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611256A1 (en) * 2005-06-10 2006-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Modulation of peripheral clocks in adipose tissue
JP4863204B2 (ja) * 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100022442A1 (en) * 2008-07-25 2010-01-28 Ambryx Biotechnology, Inc. Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels
EA034552B1 (ru) 2009-05-11 2020-02-19 БЕРГ ЭлЭлСи Способ лечения или предотвращения прогрессирования онкологических заболеваний
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
JP6731336B2 (ja) 2013-04-08 2020-07-29 バーグ エルエルシー コエンザイムｑ１０併用療法を用いた癌の処置方法
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US10530115B2 (en) * 2014-10-02 2020-01-07 ETH Zürich Pulsed laser

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
DE10044805A1 (de) * 2000-09-11 2002-04-04 Martin Klingenberg Verwendung von Coenzym Q zur Regulierung der Funktion der Entkopplerproteine
BR0114701A (pt) * 2000-10-26 2003-11-18 Fournier Lab Ireland Ltd Combinação de fenofibrato e coenzima q 10 para tratamento de disfunção endotelial
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
CA2437118A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
CA2438492A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
MXPA03007284A (es) * 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.

Also Published As

Publication number Publication date
KR20050072759A (ko) 2005-07-12
AU2003299772A1 (en) 2004-05-04
FR2845602B1 (fr) 2005-07-08
GEP20084462B (en) 2008-08-25
MY140562A (en) 2009-12-31
EA200500609A1 (ru) 2005-10-27
NZ566708A (en) 2009-11-27
AU2003299772C1 (en) 2009-08-27
EP1815858A2 (fr) 2007-08-08
CA2501964A1 (fr) 2004-04-22
CN100571776C (zh) 2009-12-23
AR041579A1 (es) 2005-05-18
JP2006505548A (ja) 2006-02-16
NO20052231L (no) 2005-05-06
EA010353B1 (ru) 2008-08-29
PL376045A1 (en) 2005-12-12
CN1703244A (zh) 2005-11-30
WO2004032967A1 (fr) 2004-04-22
EP1815858A3 (fr) 2007-12-19
US20060002911A1 (en) 2006-01-05
MXPA05003893A (es) 2005-08-03
NZ539331A (en) 2008-08-29
MA27402A1 (fr) 2005-06-01
EP1549348A1 (fr) 2005-07-06
WO2004032967A8 (fr) 2005-05-06
UA81132C2 (en) 2007-12-10
FR2845602A1 (fr) 2004-04-16
AU2003299772B2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
ES2156982T3 (es) Fluidos lubricantes para reducir la oclusion de aire y para la proteccion mejorada del engranaje.
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0008379A (pt) Epotilonas modificadas em c-21
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
DK1280541T4 (da) Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse eller behandling af fordøjelsesforstyrrelser
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
KR920019342A (ko) 골질환 치료제
KR930012022A (ko) 뇌조직 보호용 모다피닐(Modafinil)
BR0100652A (pt) Sistema hidráulico
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
AR056754A1 (es) Composiciones para el tratamiento del cabello
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
BR0314539A (pt) Associação entre um ligante dos ppar e um agente antioxidante e utilização no tratamento da obesidade
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
DK0983072T4 (da) Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer
GEP20063869B (en) Novel cyclohexyl sulphones
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.